TransCode Therapeutics, Inc. (RNAZ)

TransCode Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	7.37	5.81	2.77	4.97	20.83	0.83
Short-Term Investments	-	-	-	0.01	0.01	0
Cash & Short-Term Investments	7.37	5.81	2.77	4.98	20.84	0.83
Cash Growth	119.84%	109.97%	-44.40%	-76.11%	2406.60%	306.52%
Prepaid Expenses	0.09	0.34	0.55	1.38	1.46	-
Other Current Assets	0.6	0.94	1.14	1.02	0.44	-
Total Current Assets	8.24	7.09	4.46	7.38	22.73	0.83
Property, Plant & Equipment	0.02	0.09	0.6	0.21	0.21	-
Long-Term Deferred Charges	-	-	-	-	-	0.22
Other Long-Term Assets	-	0.11	0.11	-	-	-
Total Assets	8.27	7.29	5.17	7.59	22.94	1.06
Accrued Expenses	1.56	2.71	3.05	4.35	2.5	0.4
Current Portion of Leases	-	0.04	0.41	-	-	-
Current Unearned Revenue	-	0.03	0.03	-	0.03	-
Total Current Liabilities	1.56	2.77	3.49	4.35	2.53	0.4
Long-Term Debt	-	-	-	-	-	2.09
Long-Term Leases	-	-	0.04	-	-	-
Other Long-Term Liabilities	0.55	6.54	-	-	-	1.97
Total Liabilities	2.12	9.31	3.53	4.35	2.53	4.46
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	85.71	61.18	48.06	31.11	30.71	0.07
Retained Earnings	-79.56	-63.2	-46.42	-27.87	-10.31	-3.46
Comprehensive Income & Other	-	-	-	-	-	-0.01
Shareholders' Equity	6.15	-2.02	1.64	3.24	20.4	-3.41
Total Liabilities & Equity	8.27	7.29	5.17	7.59	22.94	1.06
Total Debt	-	0.04	0.45	-	-	2.09
Net Cash (Debt)	7.37	5.77	2.32	4.98	20.84	-1.26
Net Cash Growth	135.82%	149.15%	-53.45%	-76.11%	-	-
Net Cash Per Share	28.20	453.91	-	-	-	-
Filing Date Shares Outstanding	0.83	0.83	-	-	-	-
Total Common Shares Outstanding	0.83	0.04	-	-	-	-
Working Capital	6.68	4.32	0.96	3.03	20.2	0.43
Book Value Per Share	7.37	-54.93	-	-	-	-
Tangible Book Value	6.15	-2.02	1.64	3.24	20.4	-3.41
Tangible Book Value Per Share	7.37	-54.93	-	-	-	-
Machinery	0.36	0.36	0.38	0.35	0.25	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q